Correspondence 2021

CMS 9123 P

FDA COVID-19 Vaccines EUA to Commercial Use

OIG Anti-Kickback Statute Safe Harbors

CMS Anti-Kickback Statute Safe Harbors

NCPDP Comments to Kentucky WC regarding Pharmacy Fee Schedule

NCPDP response to FDA request for clarification on add new Marketing Category for Drug Products Produced by Federally Registered Outsourcing Facilities (OSF)

NCPDP response to the South Carolina Workers’ Comp Commission on Proposed changes to the Medical Services Provider Manual

FDA NHRIC NDC to UDI

HHS Secretary ID Card Requirements in No Surprises Act

From FDA NHRIC NDC to UDI

CMS 8 Digit NDC Transparency in Pricing Guidance

NCPDP Submission to NCVHS Request for Public Comments

CMS Real-Time Prescription Benefit and Formulary and Benefit Standards Adoption Request

NCPDP response to ONC Health Information Technology Advisory Committee (HITAC) on recommendations for using RxNorm in place of NDC

NCPDP Comments on CMS-1751-P Physician Fee Schedule

From CMS Real-Time Prescription Benefit and Formulary and Benefit Standards Adoption Request

WG1 COB Task Group Letter to Medicare Regarding QMB White Paper

WG1 COB Task Group Letter to Medicaid Regarding QMB White Paper

NCPDP Comments on DEA 21 CFR Part 1306